Reported Earnings • Apr 29
Full year 2026 earnings: Revenues exceed analysts expectations while EPS lags behind Full year 2026 results: ₹37.79 loss per share (improved from ₹68.71 loss in FY 2025). Revenue: ₹4.53b (up 19% from FY 2025). Net loss: ₹809.2m (loss narrowed 40% from FY 2025). Revenue exceeded analyst estimates by 2.6%. Earnings per share (EPS) missed analyst estimates by 61%. Revenue is forecast to grow 28% p.a. on average during the next 2 years, compared to a 13% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has fallen by 53% per year but the company’s share price has only fallen by 20% per year, which means it has not declined as severely as earnings. Announcement • Apr 28
Astec LifeSciences Limited, Annual General Meeting, Jul 31, 2026 Astec LifeSciences Limited, Annual General Meeting, Jul 31, 2026, at 16:00 Indian Standard Time. Announcement • Apr 18
Astec LifeSciences Limited to Report Q4, 2026 Results on Apr 27, 2026 Astec LifeSciences Limited announced that they will report Q4, 2026 results on Apr 27, 2026 New Risk • Mar 25
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (currently running at an operating cash loss). Minor Risk Share price has been volatile over the past 3 months (8.0% average weekly change). Announcement • Mar 10
Clean Max Enviro Energy Solutions Limited (NSEI:CLEANMAX) entered into an agreement to acquire an additional 26% stake in Clean Max Andes Private Limited from Astec LifeSciences Limited (NSEI:ASTEC) for INR 0.03 million. Clean Max Enviro Energy Solutions Limited (NSEI:CLEANMAX) entered into an agreement to acquire an additional 26% stake in Clean Max Andes Private Limited from Astec LifeSciences Limited (NSEI:ASTEC) for INR 0.03 million on March 9, 2026. A cash consideration of INR 0.03 million will be paid by Clean Max Enviro Energy Solutions Limited. As part of consideration, INR 0.03 million is paid towards common equity of Clean Max Andes Private Limited.
The expected completion of the transaction is March 10, 2026. Price Target Changed • Feb 15
Price target decreased by 10% to ₹758 Down from ₹845, the current price target is an average from 2 analysts. New target price is 19% above last closing price of ₹637. Stock is down 25% over the past year. The company is forecast to post a net loss per share of ₹22.50 next year compared to a net loss per share of ₹68.71 last year. Reported Earnings • Feb 01
Third quarter 2026 earnings: Revenues exceed analysts expectations while EPS lags behind Third quarter 2026 results: ₹7.04 loss per share (improved from ₹20.60 loss in 3Q 2025). Revenue: ₹1.26b (up 34% from 3Q 2025). Net loss: ₹157.0m (loss narrowed 61% from 3Q 2025). Revenue exceeded analyst estimates by 2.9%. Earnings per share (EPS) missed analyst estimates by 44%. Revenue is forecast to grow 29% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Chemicals industry in India. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 52 percentage points per year, which is a significant difference in performance. Announcement • Jan 20
Astec LifeSciences Limited to Report Q3, 2026 Results on Jan 30, 2026 Astec LifeSciences Limited announced that they will report Q3, 2026 results on Jan 30, 2026 New Risk • Nov 20
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 6.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (currently running at an operating cash loss). Minor Risk Share price has been volatile over the past 3 months (6.9% average weekly change). Reported Earnings • Oct 31
Second quarter 2026 earnings: EPS and revenues miss analyst expectations Second quarter 2026 results: ₹11.35 loss per share (improved from ₹19.66 loss in 2Q 2025). Revenue: ₹748.4m (down 24% from 2Q 2025). Net loss: ₹244.3m (loss narrowed 37% from 2Q 2025). Revenue missed analyst estimates by 39%. Earnings per share (EPS) also missed analyst estimates by 30%. Revenue is forecast to grow 29% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Chemicals industry in India. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 66 percentage points per year, which is a significant difference in performance. Announcement • Oct 14
Astec LifeSciences Limited to Report Q2, 2026 Results on Oct 29, 2025 Astec LifeSciences Limited announced that they will report Q2, 2026 results on Oct 29, 2025 New Risk • Aug 14
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 6.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (currently running at an operating cash loss). Minor Risk Share price has been volatile over the past 3 months (6.7% average weekly change). Board Change • Aug 01
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 4 experienced directors. 3 highly experienced directors. Independent Director Ganapati Yadav was the last director to join the board, commencing their role in 2024. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Announcement • Jul 30
Astec LifeSciences Limited has completed a Follow-on Equity Offering in the amount of INR 2.376256 billion. Astec LifeSciences Limited has completed a Follow-on Equity Offering in the amount of INR 2.376256 billion.
Security Name: Equity Shares
Security Type: Common Stock
Securities Offered: 2,669,951
Price\Range: INR 890
Transaction Features: Regulation S; Rights Offering Announcement • Jul 11
Astec LifeSciences Limited to Report Q1, 2026 Results on Jul 28, 2025 Astec LifeSciences Limited announced that they will report Q1, 2026 results on Jul 28, 2025 Reported Earnings • Jul 09
Full year 2025 earnings: EPS and revenues miss analyst expectations Full year 2025 results: ₹68.71 loss per share (further deteriorated from ₹23.94 loss in FY 2024). Revenue: ₹3.81b (down 17% from FY 2024). Net loss: ₹1.35b (loss widened 187% from FY 2024). Revenue missed analyst estimates by 39%. Earnings per share (EPS) also missed analyst estimates by 21%. Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Chemicals industry in India. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 94 percentage points per year, which is a significant difference in performance. Announcement • Jun 25
Astec LifeSciences Limited has filed a Follow-on Equity Offering in the amount of INR 2.5 billion. Astec LifeSciences Limited has filed a Follow-on Equity Offering in the amount of INR 2.5 billion.
Security Name: Equity Shares
Security Type: Common Stock
Transaction Features: Regulation S; Rights Offering Announcement • Apr 24
Astec LifeSciences Limited, Annual General Meeting, Jul 28, 2025 Astec LifeSciences Limited, Annual General Meeting, Jul 28, 2025, at 16:00 Indian Standard Time. Reported Earnings • Apr 24
Full year 2025 earnings: EPS and revenues miss analyst expectations Full year 2025 results: ₹68.71 loss per share (further deteriorated from ₹23.94 loss in FY 2024). Revenue: ₹3.87b (down 16% from FY 2024). Net loss: ₹1.35b (loss widened 187% from FY 2024). Revenue missed analyst estimates by 39%. Earnings per share (EPS) also missed analyst estimates by 21%. Revenue is forecast to grow 35% p.a. on average during the next 2 years, compared to a 12% growth forecast for the Chemicals industry in India. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 91 percentage points per year, which is a significant difference in performance. Announcement • Apr 16
Astec LifeSciences Limited to Report Q4, 2025 Results on Apr 23, 2025 Astec LifeSciences Limited announced that they will report Q4, 2025 results at 4:00 PM, Indian Standard Time on Apr 23, 2025 Price Target Changed • Feb 18
Price target decreased by 8.6% to ₹1,010 Down from ₹1,105, the current price target is an average from 2 analysts. New target price is 42% above last closing price of ₹710. Stock is down 24% over the past year. The company is forecast to post a net loss per share of ₹56.90 next year compared to a net loss per share of ₹23.93 last year. New Risk • Jan 28
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (2.4% operating cash flow to total debt). Minor Risk Share price has been volatile over the past 3 months (7.5% average weekly change). Reported Earnings • Jan 28
Third quarter 2025 earnings: EPS and revenues miss analyst expectations Third quarter 2025 results: ₹20.59 loss per share (further deteriorated from ₹12.41 loss in 3Q 2024). Revenue: ₹957.7m (up 89% from 3Q 2024). Net loss: ₹403.8m (loss widened 66% from 3Q 2024). Revenue missed analyst estimates by 3.2%. Earnings per share (EPS) also missed analyst estimates by 102%. Revenue is forecast to grow 32% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Chemicals industry in India. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 98 percentage points per year, which is a significant difference in performance. Announcement • Jan 20
Astec LifeSciences Limited to Report Q3, 2025 Results on Jan 27, 2025 Astec LifeSciences Limited announced that they will report Q3, 2025 results on Jan 27, 2025 Announcement • Dec 15
Astec Lifesciences Limited Announces Appointment of Arijit Mukherjee as the Manager Astec LifeSciences Limited passed resolution on December 14, 2024, Appointment of Mr. Arijit Mukherjee, Chief Operating Officer, as the "Manager" of the Company (within the meaning of Section 2(53) of the Companies Act, 2013) with effect from 26th October, 2024 for a term of 3 (Three) years, i.e., upto 25th October, 2027, has been approved by the Shareholders by way of a Special Resolution. Reported Earnings • Oct 26
Second quarter 2025 earnings: EPS and revenues miss analyst expectations Second quarter 2025 results: ₹19.66 loss per share (further deteriorated from ₹6.85 loss in 2Q 2024). Revenue: ₹1.01b (down 9.2% from 2Q 2024). Net loss: ₹385.6m (loss widened 187% from 2Q 2024). Revenue missed analyst estimates by 16%. Earnings per share (EPS) also missed analyst estimates by 22%. Revenue is forecast to grow 31% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Chemicals industry in India. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 99 percentage points per year, which is a significant difference in performance. Announcement • Oct 04
Astec Lifesciences Limited Announces Resignation of Brahma Nand Vyas as an Independent Director Astec LifeSciences Limited announced that Dr. Brahma Nand Vyas has tendered his resignation as an Independent Director of the Company with effect from closure of business hours on 4th October, 2024, due to his advancing age. Reason for Change: Dr. Brahma Nand Vyas has tendered his resignation as an Independent Director of the Company, with effect from closure of business hours on 4th October, 2024, due to his advancing age. Announcement • Sep 23
Astec Lifesciences Limited Announces Resignation of Anurag Roy as Chief Executive Officer, Effective October 25, 2024 Astec LifeSciences Limited announced that Mr. Anurag Roy has tendered his resignation as Chief Executive Officer with effect from closure of business hours on 25th October, 2024. Reason for Change: Mr. Anurag Roy has tendered his resignation as the Whole Time Director & Chief Executive Officer of the Company, with effect from closure of business hours on 25th October, 2024, for pursuing opportunities outside the Company. Date of Cessation: Closure of business hours on 25th October, 2024. Price Target Changed • Sep 23
Price target decreased by 14% to ₹1,090 Down from ₹1,273, the current price target is an average from 2 analysts. New target price is 9.3% below last closing price of ₹1,202. Stock is down 8.4% over the past year. The company is forecast to post earnings per share of ₹10.30 next year compared to a net loss per share of ₹23.93 last year. Announcement • Sep 23
Astec Lifesciences Limited Announces Resignation of Anurag Roy as the Whole Time Director, Effective October 25, 2024 Astec LifeSciences Limited announced that Mr. Anurag Roy has tendered his resignation as the Whole Time Director of the Company with effect from closure of business hours on 25th October, 2024. Reason for Change: Mr. Anurag Roy has tendered his resignation as the Whole Time Director & Chief Executive Officer of the Company, with effect from closure of business hours on 25th October, 2024, for pursuing opportunities outside the Company. Date of Cessation: Closure of business hours on 25th October, 2024. New Risk • Aug 07
New major risk - Revenue and earnings growth Earnings have declined by 31% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (2.1% operating cash flow to total debt). Earnings have declined by 31% per year over the past 5 years. Board Change • Aug 01
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 4 experienced directors. 4 highly experienced directors. Additional Non-Executive Non- Independent Director Burjis Godrej was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Announcement • Jul 18
Astec LifeSciences Limited to Report Q1, 2025 Results on Jul 29, 2024 Astec LifeSciences Limited announced that they will report Q1, 2025 results on Jul 29, 2024 Reported Earnings • Jul 08
Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind Full year 2024 results: ₹23.94 loss per share (down from ₹13.04 profit in FY 2023). Revenue: ₹4.59b (down 27% from FY 2023). Net loss: ₹469.3m (down 284% from profit in FY 2023). Revenue exceeded analyst estimates by 6.6%. Earnings per share (EPS) missed analyst estimates by 10%. Revenue is forecast to grow 31% p.a. on average during the next 2 years, compared to a 12% growth forecast for the Chemicals industry in India. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 74 percentage points per year, which is a significant difference in performance. Announcement • May 03
Astec LifeSciences Limited, Annual General Meeting, Jul 29, 2024 Astec LifeSciences Limited, Annual General Meeting, Jul 29, 2024, at 16:00 Indian Standard Time. Reported Earnings • May 03
Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind Full year 2024 results: ₹0.50 loss per share (down from ₹13.04 profit in FY 2023). Revenue: ₹1.56b (down 75% from FY 2023). Net loss: ₹9.74m (down 104% from profit in FY 2023). Revenue exceeded analyst estimates by 6.6%. Earnings per share (EPS) missed analyst estimates by 10%. Revenue is forecast to grow 63% p.a. on average during the next 2 years, compared to a 12% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has fallen by 61% per year but the company’s share price has increased by 3% per year, which means it is well ahead of earnings. Announcement • Apr 26
Astec LifeSciences Limited to Report Q4, 2024 Results on May 02, 2024 Astec LifeSciences Limited announced that they will report Q4, 2024 results on May 02, 2024 Price Target Changed • Apr 14
Price target decreased by 14% to ₹1,108 Down from ₹1,285, the current price target is an average from 2 analysts. New target price is 14% below last closing price of ₹1,289. Stock is down 5.2% over the past year. The company is forecast to post a net loss per share of ₹21.70 compared to earnings per share of ₹13.04 last year. Price Target Changed • Jan 28
Price target decreased by 9.3% to ₹1,205 Down from ₹1,328, the current price target is an average from 2 analysts. New target price is 20% above last closing price of ₹1,001. Stock is down 35% over the past year. The company posted earnings per share of ₹13.04 last year. Reported Earnings • Jan 27
Third quarter 2024 earnings released: ₹12.41 loss per share (vs ₹0.43 profit in 3Q 2023) Third quarter 2024 results: ₹12.41 loss per share (down from ₹0.43 profit in 3Q 2023). Revenue: ₹517.0m (down 56% from 3Q 2023). Net loss: ₹243.3m (down ₹251.7m from profit in 3Q 2023). Revenue is forecast to grow 35% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has fallen by 54% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings. Announcement • Jan 13
Astec LifeSciences Limited to Report Q3, 2024 Results on Jan 25, 2024 Astec LifeSciences Limited announced that they will report Q3, 2024 results at 4:00 PM, Indian Standard Time on Jan 25, 2024 Reported Earnings • Oct 29
Second quarter 2024 earnings released: ₹6.85 loss per share (vs ₹9.34 profit in 2Q 2023) Second quarter 2024 results: ₹6.85 loss per share (down from ₹9.34 profit in 2Q 2023). Revenue: ₹1.12b (down 44% from 2Q 2023). Net loss: ₹134.3m (down 173% from profit in 2Q 2023). Over the last 3 years on average, earnings per share has fallen by 34% per year but the company’s share price has increased by 2% per year, which means it is well ahead of earnings. Announcement • Oct 11
Astec LifeSciences Limited to Report Q2, 2024 Results on Oct 27, 2023 Astec LifeSciences Limited announced that they will report Q2, 2024 results on Oct 27, 2023 Announcement • Jul 29
Astec LifeSciences Limited Declares Final Dividend for the Financial Year Ended March 31, 2023 Astec LifeSciences Limited announced at the AGM held on July 27, 2023, approved to declare final dividend on equity share @15%(that is INR 1.5) per equity share of face value of INR 10 for the financial year ended March 31, 2023. Announcement • Jul 23
Astec LifeSciences Limited to Report Q1, 2024 Results on Jul 27, 2023 Astec LifeSciences Limited announced that they will report Q1, 2024 results on Jul 27, 2023 Upcoming Dividend • Jul 14
Upcoming dividend of ₹1.50 per share at 0.1% yield Eligible shareholders must have bought the stock before 21 July 2023. Payment date: 01 August 2023. Payout ratio is a comfortable 12% but the company is not cash flow positive. Trailing yield: 0.1%. Lower than top quartile of Indian dividend payers (1.5%). Lower than average of industry peers (0.9%). Reported Earnings • Jul 08
Full year 2023 earnings released: EPS: ₹13.04 (vs ₹45.87 in FY 2022) Full year 2023 results: EPS: ₹13.04 (down from ₹45.87 in FY 2022). Revenue: ₹6.28b (down 7.2% from FY 2022). Net income: ₹255.6m (down 72% from FY 2022). Profit margin: 4.1% (down from 13% in FY 2022). The decrease in margin was primarily driven by lower revenue. Revenue is forecast to grow 22% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has increased by 11% per year, which means it is tracking significantly ahead of earnings growth. Recent Insider Transactions • Jun 10
Non-Executive Non-Independent Director recently sold ₹4.8m worth of stock On the 6th of June, Balram Yadav sold around 3k shares on-market at roughly ₹1,407 per share. This transaction amounted to 100% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months. Announcement • May 04
Astec LifeSciences Limited Recommends Final Dividend for the Financial Year Ended March 31, 2023, Payable by August 1, 2023 Astec LifeSciences Limited at its board meeting held on May 2, 2023, recommended Final Dividend of 15% on the Equity Share Capital of the Company that is INR 1.50 per Equity Share of Face Value of INR 10 each for the Financial Year ended March 31, 2023, subject To Approve the Shareholders at the upcoming 29th Annual General Meeting of the Company. The Book Closure Dates for the purposes of the 29th Annual General Meeting and payment of Final Dividend are from July 22, 2023 to July 26, 2023, during which the Register of Members and Share Transfer Books will remain closed. The dividend will be paid by August 1, 2023. Reported Earnings • May 03
Full year 2023 earnings released: EPS: ₹13.04 (vs ₹45.87 in FY 2022) Full year 2023 results: EPS: ₹13.04 (down from ₹45.87 in FY 2022). Revenue: ₹6.41b (down 5.3% from FY 2022). Net income: ₹255.6m (down 72% from FY 2022). Profit margin: 4.0% (down from 13% in FY 2022). The decrease in margin was primarily driven by lower revenue. Revenue is forecast to grow 23% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has increased by 37% per year, which means it is tracking significantly ahead of earnings growth. Valuation Update With 7 Day Price Move • Apr 04
Investor sentiment improves as stock rises 23% After last week's 23% share price gain to ₹1,346, the stock trades at a forward P/E ratio of 31x. Average forward P/E is 23x in the Chemicals industry in India. Total returns to shareholders of 204% over the past three years. Reported Earnings • Jan 31
Third quarter 2023 earnings released: EPS: ₹0.43 (vs ₹12.63 in 3Q 2022) Third quarter 2023 results: EPS: ₹0.43 (down from ₹12.63 in 3Q 2022). Revenue: ₹1.21b (down 30% from 3Q 2022). Net income: ₹8.40m (down 97% from 3Q 2022). Profit margin: 0.7% (down from 14% in 3Q 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has increased by 42% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Jan 12
Astec LifeSciences Limited to Report Q3, 2023 Results on Jan 30, 2023 Astec LifeSciences Limited announced that they will report Q3, 2023 results on Jan 30, 2023 Price Target Changed • Jan 05
Price target decreased to ₹1,923 Down from ₹2,083, the current price target is an average from 3 analysts. New target price is 11% above last closing price of ₹1,739. Stock is up 19% over the past year. The company is forecast to post earnings per share of ₹46.90 for next year compared to ₹45.87 last year. Board Change • Nov 16
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Additional Non-Executive Non- Independent Director Burjis Godrej was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Nov 03
Second quarter 2023 earnings released: EPS: ₹9.34 (vs ₹4.63 in 2Q 2022) Second quarter 2023 results: EPS: ₹9.34 (up from ₹4.63 in 2Q 2022). Revenue: ₹2.00b (up 95% from 2Q 2022). Net income: ₹183.1m (up 102% from 2Q 2022). Profit margin: 9.2% (up from 8.8% in 2Q 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has increased by 81% per year, which means it is tracking significantly ahead of earnings growth. Valuation Update With 7 Day Price Move • Oct 17
Investor sentiment improved over the past week After last week's 18% share price gain to ₹2,176, the stock trades at a forward P/E ratio of 40x. Average forward P/E is 28x in the Chemicals industry in India. Total returns to shareholders of 525% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₹3,619 per share. Price Target Changed • Aug 30
Price target increased to ₹2,132 Up from ₹1,875, the current price target is an average from 2 analysts. New target price is 10% above last closing price of ₹1,930. Stock is up 48% over the past year. The company is forecast to post earnings per share of ₹50.00 for next year compared to ₹45.87 last year. Board Change • Aug 02
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Additional Non-Executive Non- Independent Director Burjis Godrej was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Upcoming Dividend • Jul 12
Upcoming dividend of ₹1.50 per share Eligible shareholders must have bought the stock before 19 July 2022. Payment date: 29 July 2022. Payout ratio is a comfortable 3.3% but the company is not cash flow positive. Trailing yield: 0.1%. Lower than top quartile of Indian dividend payers (1.8%). Lower than average of industry peers (0.8%). Reported Earnings • Jul 06
Full year 2022 earnings: Revenues exceed analyst expectations Full year 2022 results: Net income: ₹898.6m (up 38% from FY 2021). Revenue exceeded analyst estimates by 3.8%. Price Target Changed • May 19
Price target increased to ₹1,869 Up from ₹1,722, the current price target is an average from 4 analysts. New target price is approximately in line with last closing price of ₹1,794. Stock is up 43% over the past year. The company is forecast to post earnings per share of ₹54.93 for next year compared to ₹45.87 last year. Major Estimate Revision • May 09
Consensus revenue estimates increase by 11% The consensus outlook for revenues in 2023 has improved. 2023 revenue forecast increased from ₹7.68b to ₹8.52b. EPS estimate increased from ₹48.30 to ₹54.93 per share. Net income forecast to grow 24% next year vs 25% growth forecast for Chemicals industry in India. Consensus price target up from ₹1,722 to ₹1,812. Share price fell 3.9% to ₹1,874 over the past week. Reported Earnings • May 04
Full year 2022 earnings: EPS and revenues exceed analyst expectations Full year 2022 results: EPS: ₹45.87 (up from ₹33.23 in FY 2021). Revenue: ₹6.87b (up 23% from FY 2021). Net income: ₹898.6m (up 38% from FY 2021). Profit margin: 13% (up from 12% in FY 2021). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 3.8%. Earnings per share (EPS) also surpassed analyst estimates by 6.9%. Over the next year, revenue is forecast to grow 12%, compared to a 21% growth forecast for the industry in India. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has increased by 56% per year, which means it is tracking significantly ahead of earnings growth. Recent Insider Transactions • Apr 02
MD & Director recently bought ₹37m worth of stock On the 25th of March, Ashok Hiremath bought around 22k shares on-market at roughly ₹1,701 per share. This was the largest purchase by an insider in the last 3 months. Despite this recent purchase, insiders have collectively sold ₹213m more in shares than they bought in the last 12 months. Recent Insider Transactions • Mar 11
Non-Executive Non-Independent Director recently bought ₹1.5m worth of stock On the 7th of March, Balram Yadav bought around 1k shares on-market at roughly ₹1,481 per share. In the last 3 months, they made an even bigger purchase worth ₹3.5m. Despite this recent purchase, insiders have collectively sold ₹251m more in shares than they bought in the last 12 months. Recent Insider Transactions • Mar 06
Non-Executive Non-Independent Director recently bought ₹3.5m worth of stock On the 28th of February, Balram Yadav bought around 2k shares on-market at roughly ₹1,467 per share. This was the largest purchase by an insider in the last 3 months. Despite this recent purchase, insiders have collectively sold ₹252m more in shares than they bought in the last 12 months. Reported Earnings • Jan 26
Third quarter 2022 earnings: EPS and revenues exceed analyst expectations Third quarter 2022 results: EPS: ₹12.63 (up from ₹3.61 in 3Q 2021). Revenue: ₹1.75b (up 51% from 3Q 2021). Net income: ₹247.5m (up 251% from 3Q 2021). Profit margin: 14% (up from 6.1% in 3Q 2021). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 2.5%. Earnings per share (EPS) also surpassed analyst estimates by 19%. Over the next year, revenue is forecast to grow 24%, compared to a 19% growth forecast for the industry in India. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has increased by 50% per year, which means it is tracking significantly ahead of earnings growth. Recent Insider Transactions • Dec 18
Insider recently sold ₹1.5m worth of stock On the 13th of December, Ramesh Pingale sold around 1k shares on-market at roughly ₹1,508 per share. In the last 3 months, they made an even bigger sale worth ₹2.4m. Insiders have been net sellers, collectively disposing of ₹254m more than they bought in the last 12 months. Recent Insider Transactions • Dec 18
Insider recently sold ₹1.5m worth of stock On the 13th of December, Ramesh Pingale sold around 1k shares on-market at roughly ₹1,508 per share. In the last 3 months, they made an even bigger sale worth ₹2.4m. Insiders have been net sellers, collectively disposing of ₹254m more than they bought in the last 12 months. Valuation Update With 7 Day Price Move • Dec 13
Investor sentiment improved over the past week After last week's 16% share price gain to ₹1,553, the stock trades at a forward P/E ratio of 35x. Average forward P/E is 31x in the Chemicals industry in India. Total returns to shareholders of 202% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₹952 per share. Recent Insider Transactions • Nov 20
Insider recently sold ₹2.4m worth of stock On the 15th of November, Ramesh Pingale sold around 2k shares on-market at roughly ₹1,401 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of ₹253m more than they bought in the last 12 months. Price Target Changed • Nov 16
Price target increased to ₹1,508 Up from ₹1,392, the current price target is an average from 3 analysts. New target price is 10% above last closing price of ₹1,367. Stock is up 39% over the past year. The company is forecast to post earnings per share of ₹39.25 for next year compared to ₹33.23 last year. Price Target Changed • Aug 01
Price target increased to ₹1,386 Up from ₹1,284, the current price target is an average from 4 analysts. New target price is approximately in line with last closing price of ₹1,388. Stock is up 48% over the past year. Upcoming Dividend • Jul 16
Upcoming dividend of ₹1.50 per share Eligible shareholders must have bought the stock before 22 July 2021. Payment date: 27 August 2021. Trailing yield: 0.1%. Lower than top quartile of Indian dividend payers (1.5%). Lower than average of industry peers (0.7%). Reported Earnings • Jul 06
Full year 2021 earnings released: EPS ₹33.23 (vs ₹24.29 in FY 2020) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: ₹5.59b (up 5.7% from FY 2020). Net income: ₹650.5m (up 37% from FY 2020). Profit margin: 12% (up from 9.0% in FY 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 31% per year whereas the company’s share price has increased by 29% per year. Recent Insider Transactions • May 28
Whole Time Director recently sold ₹2.9m worth of stock On the 24th of May, Arijit Mukherjee sold around 2k shares on-market at roughly ₹1,428 per share. In the last 3 months, there was an even bigger sale from another insider worth ₹240m. Insiders have been net sellers, collectively disposing of ₹1.2b more than they bought in the last 12 months. Valuation Update With 7 Day Price Move • May 26
Investor sentiment improved over the past week After last week's 16% share price gain to ₹1,466, the stock trades at a forward P/E ratio of 39x. Average forward P/E is 31x in the Chemicals industry in India. Total returns to shareholders of 107% over the past three years. 
